About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Dnase2atm1Osa
targeted mutation 1, Shigekazu Nagata
MGI:2449811
Summary 6 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
hm1
Dnase2atm1Osa/Dnase2atm1Osa involves: 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:3040432
cn2
Dnase2atm1Osa/Dnase2atm2Osa
Tg(Mx1-cre)1Cgn/0
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA MGI:3692382
cx3
Aim2tm1.2Arte/Aim2tm1.2Arte
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt
involves: 129 * BALB/c * C57BL/6 * C57BL/6J MGI:5823437
cx4
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 MGI:3526798
cx5
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt
Xkr8tm1.2Osa/Xkr8tm1.2Osa
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 MGI:7614309
cx6
Dffbtm1Osa/Dffbtm1Osa
Dnase2atm1Osa/Dnase2atm1Osa
involves: 129S1/Sv * 129X1/SvJ * C57BL/6 MGI:3694082


Genotype
MGI:3040432
hm1
Allelic
Composition
Dnase2atm1Osa/Dnase2atm1Osa
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dnase2atm1Osa mutation (2 available); any Dnase2a mutation (92 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• no live homozygous mutant animals were recovered, although they were present at a frequency roughly consistent with Mendelian inheritance throughout embryonic development

hematopoietic system
• many large abnormal foci containing macrophage with fragmented DNA
• cellularity 29% of controls
• homozygous null mice displayed impaired definitive erythropoiesis in the fetal liver and spleen
• the numbers of CFU-E (colony-forming unit, erythroid) as well as BFU-E (burst-forming unit, erythroid), CFU-G (granulocyte), and CFU-M (macrophage) in the E12.5 fetal liver were similar between wild-type and homozygous null embryos
• diaminofluorene staining revealed that mutant erythroid cells were able to differentiate into hemoglobin-producing cells
• in colonies of CFU-E generated with either wild-type or homozygous null fetal liver cells, about 10% of cells were enucleated
• when homozygous null fetal liver cells were transferred into lethally-irradiated wild-type mice, mature red blood cells were generated from the mutant cells, suggesting that impairment of definitive erythropoiesis was due to a non-cell-autonomous effect
• histochemical analysis of E12.5 to E17.5 mutant fetal livers revealed reduced cellularity relative to wild-type, as well as the presence of abnormal foci of various sizes
• electron transmission microscopy combined with immunohistochemical analysis of E12.5 to E17.5 mutant fetal livers revealed accumulation of a large amount of DNA, as well as the presence of macrophage-like cells which were often surrounded by erythroid cells at various stages of differentiation
• these findings suggested that macrophage enzyme activity is required for degradation of nuclear DNA expelled during erythrocyte maturation
• some homozygous null embryos became paler than normal at E14.5, and all mutant embryos were severely anemic by E17.5; no other abnormalities besides anemia were observed at E17.5
• up to E12.5, a normal level of vasculature was noted in the homozygous null embryos and yolk sac
• at E12.5, similar numbers of nucleated primitive erythrocytes were observed in the peripheral blood of wild-type and homozygous null embryos
• however, the number of mature erythrocytes in the peripheral blood of homozygous null embryos was less than 1/10th of that present in normal controls at E17.5
• no hemolysis was observed
• the peripheral blood of mutant embryos contained nucleated erythrocytes, which were not erythrosin-positive primitive erythrocytes, but appeared to be erythroblasts that had not undergone enucleation (J:69831)

immune system
• many large abnormal foci containing macrophage with fragmented DNA
• cellularity 29% of controls

endocrine/exocrine glands
• many large abnormal foci containing macrophage with fragmented DNA
• cellularity 29% of controls




Genotype
MGI:3692382
cn2
Allelic
Composition
Dnase2atm1Osa/Dnase2atm2Osa
Tg(Mx1-cre)1Cgn/0
Genetic
Background
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dnase2atm1Osa mutation (2 available); any Dnase2a mutation (92 available)
Dnase2atm2Osa mutation (1 available); any Dnase2a mutation (92 available)
Tg(Mx1-cre)1Cgn mutation (7 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• pI-pC treated mutants are growth retarded

immune system
• pI-pC treated mutants exhibit numerous abnormal macrophages that contain DNA in lysosomes in the bone marrow, spleen and other tissues
• affected joints of pI-pC treated mutants show 5-100 fold elevation of TNF-alpha, IL-1beta, IL-6, IL-10, IFN-beta, and IFN-gamma mRNA levels, the set of cytokines that are elevated in joints of humans with rheumatoid arthritis
• serum pI-pC treated mutants shows elevated levels of IL-18 protein
• serum of pI-pC treated mutants shows elevated levels of TNF-alpha before joints show abnormalities
• joints of pI-pC treated mutants show severe synovitis with villus proliferation accompanied by pannus formation; pannus fills the joint cavity, erodes cartilage, destroys bones, and occasionally penetrates the bone marrow
• exhibit infiltration of subsynovial tissues by T cells and neutrophils
• poly(I)-poly(C) (pI-pC) treated mutants develop polyarthritis in a time-dependent manner; forelimbs and hindlimbs begin to swell 2-3 months after pI-pC treatment
• swelling first affects the digits, then the foot, and finally the wrists and ankles

hematopoietic system
• pI-pC treated mutants are slightly anemic
• pI-pC treated mutants exhibit numerous abnormal macrophages that contain DNA in lysosomes in the bone marrow, spleen and other tissues

homeostasis/metabolism
• pI-pC treated mutants carry a low but significant level of DNA in serum
• affected joints of pI-pC treated mutants show 5-100 fold elevation of TNF-alpha, IL-1beta, IL-6, IL-10, IFN-beta, and IFN-gamma mRNA levels, the set of cytokines that are elevated in joints of humans with rheumatoid arthritis
• serum pI-pC treated mutants shows elevated levels of IL-18 protein
• serum of pI-pC treated mutants shows elevated levels of TNF-alpha before joints show abnormalities

skeleton
• joints of pI-pC treated mutants show severe synovitis with villus proliferation accompanied by pannus formation; pannus fills the joint cavity, erodes cartilage, destroys bones, and occasionally penetrates the bone marrow
• exhibit infiltration of subsynovial tissues by T cells and neutrophils
• poly(I)-poly(C) (pI-pC) treated mutants develop polyarthritis in a time-dependent manner; forelimbs and hindlimbs begin to swell 2-3 months after pI-pC treatment
• swelling first affects the digits, then the foot, and finally the wrists and ankles

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
rheumatoid arthritis DOID:7148 OMIM:180300
J:114982




Genotype
MGI:5823437
cx3
Allelic
Composition
Aim2tm1.2Arte/Aim2tm1.2Arte
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt
Genetic
Background
involves: 129 * BALB/c * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Aim2tm1.2Arte mutation (0 available); any Aim2 mutation (32 available)
Dnase2atm1Osa mutation (2 available); any Dnase2a mutation (92 available)
Ifnar1tm1Agt mutation (11 available); any Ifnar1 mutation (59 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
hematopoietic system
• increase in expression of IFN-beta in splenic tissue
• splenomegaly, with spleen sizes being 4-5 fold increased

homeostasis/metabolism

immune system
• increase in expression of IFN-beta in splenic tissue
• splenomegaly, with spleen sizes being 4-5 fold increased
• presence of anti-cyclic citrullinated peptide antibodies
• signs of polyarthritis are reduced compared to double Dnase2a and Ifnar1 homozygotes, although mice do show some arthritis development
• joints do not show an increase in cleaved caspase-1
• expression of pro-inflammatory cytokines, such as TNF, IL-6, and IL-1beta, is reduced both at protein and mRNA level in joints compared to double Dnase2a and Ifnar1 homozygotes
• mice show decreased macrophage infiltration in joints compared to double Dnase2a and Ifnar1 homozygotes

skeleton
• signs of polyarthritis are reduced compared to double Dnase2a and Ifnar1 homozygotes, although mice do show some arthritis development
• joints do not show an increase in cleaved caspase-1
• expression of pro-inflammatory cytokines, such as TNF, IL-6, and IL-1beta, is reduced both at protein and mRNA level in joints compared to double Dnase2a and Ifnar1 homozygotes
• mice show decreased macrophage infiltration in joints compared to double Dnase2a and Ifnar1 homozygotes

growth/size/body
• splenomegaly, with spleen sizes being 4-5 fold increased




Genotype
MGI:3526798
cx4
Allelic
Composition
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt
Genetic
Background
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dnase2atm1Osa mutation (2 available); any Dnase2a mutation (92 available)
Ifnar1tm1Agt mutation (11 available); any Ifnar1 mutation (59 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• develop splenomegaly from 1 month of age, which becomes prominent as mutants age (J:114982)
• splenomegaly, with spleen sizes being 4-5 fold increased (J:238323)

immune system
• exhibit numerous abnormal macrophages that contain DNA in lysosomes in the bone marrow, spleen and other tissues
• increase in expression of IFN-beta in splenic tissue
• develop splenomegaly from 1 month of age, which becomes prominent as mutants age (J:114982)
• splenomegaly, with spleen sizes being 4-5 fold increased (J:238323)
• splenomegaly due to enlargement of the red pulp
• affected joints show 5-100 fold elevation of TNF-alpha, IL-1beta, IL-6, IL-10, IFN-beta, and IFN-gamma mRNA levels, the set of cytokines that are elevated in joints of humans with rheumatoid arthritis
• serum shows elevated levels of IL-18 protein
• serum shows elevated levels of TNF-alpha at 4-6 weeks of age, before joints show abnormalities; the extend of elevation decreases as mutants age (J:114982)
• presence of anti-cyclic citrullinated peptide antibodies
• level of anti-double-stranded DNA antibody is elevated 3-fold
• joints of show severe synovitis with villus proliferation accompanied by pannus formation; pannus fills the joint cavity, erodes cartilage, destroys bones, and occasionally penetrates the bone marrow (J:114982)
• exhibit infiltration of subsynovial tissues by T cells and neutrophils (J:114982)
• joints show severe signs of synovitis with hyperproliferation of synovial cells and massive immune cell infiltration at 15 months of age, associated with panus formation, cartilage destruction, and bone erosion (J:238323)
• develop polyarthritis as age; forelimbs and hindlimbs begin to swell at 2-3 months of age and swelling first affects the digits, then the foot and finally the wrists and ankles (J:114982)
• mice develop chronic polyarthritis that progresses with age (J:238323)
• joints show an increase in cleaved caspase-1, indicating signs of inflammasome activation (J:238323)
• expression of pro-inflammatory cytokines such as TNF, IL-6, and IL-1beta is increased both at protein and mRNA level in joints (J:238323)
• immune cell infiltrate is mainly dominated by presence of macrophages (J:238323)

hematopoietic system
• slightly anemic
• exhibit numerous abnormal macrophages that contain DNA in lysosomes in the bone marrow, spleen and other tissues
• increase in expression of IFN-beta in splenic tissue
• develop splenomegaly from 1 month of age, which becomes prominent as mutants age (J:114982)
• splenomegaly, with spleen sizes being 4-5 fold increased (J:238323)
• splenomegaly due to enlargement of the red pulp

homeostasis/metabolism
• carry a significant level of DNA in serum which decreases as mutants age
• affected joints show 5-100 fold elevation of TNF-alpha, IL-1beta, IL-6, IL-10, IFN-beta, and IFN-gamma mRNA levels, the set of cytokines that are elevated in joints of humans with rheumatoid arthritis
• serum shows elevated levels of IL-18 protein
• serum shows elevated levels of TNF-alpha at 4-6 weeks of age, before joints show abnormalities; the extend of elevation decreases as mutants age (J:114982)

skeleton
• joints of show severe synovitis with villus proliferation accompanied by pannus formation; pannus fills the joint cavity, erodes cartilage, destroys bones, and occasionally penetrates the bone marrow (J:114982)
• exhibit infiltration of subsynovial tissues by T cells and neutrophils (J:114982)
• joints show severe signs of synovitis with hyperproliferation of synovial cells and massive immune cell infiltration at 15 months of age, associated with panus formation, cartilage destruction, and bone erosion (J:238323)
• develop polyarthritis as age; forelimbs and hindlimbs begin to swell at 2-3 months of age and swelling first affects the digits, then the foot and finally the wrists and ankles (J:114982)
• mice develop chronic polyarthritis that progresses with age (J:238323)
• joints show an increase in cleaved caspase-1, indicating signs of inflammasome activation (J:238323)
• expression of pro-inflammatory cytokines such as TNF, IL-6, and IL-1beta is increased both at protein and mRNA level in joints (J:238323)
• immune cell infiltrate is mainly dominated by presence of macrophages (J:238323)

Mouse Models of Human Disease
DO ID OMIM ID(s) Ref(s)
rheumatoid arthritis DOID:7148 OMIM:180300
J:114982 , J:238323




Genotype
MGI:7614309
cx5
Allelic
Composition
Dnase2atm1Osa/Dnase2atm1Osa
Ifnar1tm1Agt/Ifnar1tm1Agt
Xkr8tm1.2Osa/Xkr8tm1.2Osa
Genetic
Background
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dnase2atm1Osa mutation (2 available); any Dnase2a mutation (92 available)
Ifnar1tm1Agt mutation (11 available); any Ifnar1 mutation (59 available)
Xkr8tm1.2Osa mutation (2 available); any Xkr8 mutation (17 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
reproductive system
• at 3 weeks of age, apoptotic germ cells are not engulfed by Sertoli cells; the number of Sertoli cells carrying undigested DNA (foci) is significantly lower than that in testes that are heterozygous for Xkr8tm1.2Osa and homozygous for both Dnase2atm1Osa and Ifnar1tm1Agt
• although abnormal foci are less abundant, many clusters of hematoxylin-positive materials are found in peripheral regions of the testicular tubes, suggesting that these represent unengulfed apoptotic bodies with condensed and fragmented nuclei




Genotype
MGI:3694082
cx6
Allelic
Composition
Dffbtm1Osa/Dffbtm1Osa
Dnase2atm1Osa/Dnase2atm1Osa
Genetic
Background
involves: 129S1/Sv * 129X1/SvJ * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Dffbtm1Osa mutation (2 available); any Dffb mutation (27 available)
Dnase2atm1Osa mutation (2 available); any Dnase2a mutation (92 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
growth/size/body
• slightly smaller than controls

hematopoietic system
• many large abnormal foci containing macrophage with intact DNA filaments
• cellularity 12% of controls
• T cell development inhibited at an early progenitor stage
• about 1/3 the level seen in controls

immune system
• many large abnormal foci containing macrophage with intact DNA filaments
• cellularity 12% of controls
• T cell development inhibited at an early progenitor stage
• about 1/3 the level seen in controls

endocrine/exocrine glands
• many large abnormal foci containing macrophage with intact DNA filaments
• cellularity 12% of controls





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Models of Human Cancer database (MMHCdb) (formerly Mouse Tumor Biology (MTB)), Gene Ontology (GO)
Citing These Resources
Funding Information
Warranty Disclaimer, Privacy Notice, Licensing, & Copyright
Send questions and comments to User Support.
last database update
04/16/2024
MGI 6.23
The Jackson Laboratory